ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Fraser W.H. Sutherland
Kristine J. Guleserian
John E. Mayer
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perry, T. E.
Right arrow Articles by Mayer, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perry, T. E.
Right arrow Articles by Mayer, J. E.
Related Collections
Right arrow Molecular biology

Ann Thorac Surg 2003;75:761-767
© 2003 The Society of Thoracic Surgeons

Thoracic Surgery Directors Association Award

Bone marrow as a cell source for tissue engineering heart valves

Tjörvi E. Perry, MD*a, Sunjay Kaushal, MD, PhDa, Fraser W.H. Sutherland, MDa, Kristine J. Guleserian, MDa, Joyce Bischoff, PhDb, Michael Sacks, PhDc, John E. Mayer, MDa

a Department of Cardiac Surgery, Children’s Hospital, Boston, Massachusetts, USA
b Department of Surgery, Children’s Hospital, Boston, Massachusetts, USA
c Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

* Address reprint requests to Dr Perry, Department of Cardiac Surgery, 300 Longwood Ave, Boston, MA 02115, USA
e-mail: tjorviperry{at}cs.com

Presented at the Thirty-eighth Annual Meeting of The Society of Thoracic Surgeons, Fort Lauderdale, FL, Jan 28–30, 2002.

BACKGROUND: This study was designed to assess the feasibility of using ovine bone marrow-derived mesenchymal stem cells to develop a trileaflet heart valve using a tissue engineering approach.

METHODS: Bone marrow was aspirated from the sternum of adult sheep. Cells were isolated using a Ficoll gradient, cultured, and characterized based on immunofluorescent staining and the ability to differentiate down a specific cell lineage. Two million cells per centimeter squared were delivered onto a polyglycolic acid (PGA), poly-4-hydroxybutyrate (P4HB) composite scaffold and cultured for 1 week before being transferred to a pulse duplicator for an additional 2 weeks. The tissue-engineered valves were assessed by histology, scanning electron microscopy, and biomechanical flexure testing.

RESULTS: Cells expressed SH2, a marker for mesenchymal stem cells, as well as specific markers of smooth muscle cell lineage including {alpha}-smooth muscle actin, desmin, and calponin. These cells could be induced to differentiate down an adipocyte lineage confirming they had not fully committed to a specific cell lineage. Preliminary histologic examination showed patchy surface confluency confirmed by scanning electron microscopy, and deep cellular material. Biomechanical flexure testing of the leaflets showed an effective stiffness comparable to normal valve leaflets.

CONCLUSIONS: Mesenchymal stem cells can be isolated noninvasively from the sternum of sheep and can adhere to and populate a PGA/P4HB composite scaffold to form "tissue" that has biomechanical properties similar to native heart valve leaflets. Thus, bone marrow may be a potential source of cells for tissue engineering trileaflet heart valves, particularly in children with congenital heart disease.




This article has been cited by other articles:


Home page
 Eur. J. Cardiothorac. Surg.Home page
M. Siepe, P. Akhyari, A. Lichtenberg, C. Schlensak, and F. Beyersdorf
Stem cells used for cardiovascular tissue engineering.
Eur. J. Cardiothorac. Surg., August 1, 2008; 34(2): 242 - 247.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
B. A. Mettler, V. L. Sales, C. L. Stucken, V. Anttila, K. Mendelson, J. Bischoff, and J. E. Mayer Jr
Stem cell-derived, tissue-engineered pulmonary artery augmentation patches in vivo.
Ann. Thorac. Surg., July 1, 2008; 86(1): 132 - 141.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
Z. Gong and L. E. Niklason
Small-diameter human vessel wall engineered from bone marrow-derived mesenchymal stem cells (hMSCs)
FASEB J, June 1, 2008; 22(6): 1635 - 1648.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
D Mrugala, C Bony, N Neves, L Caillot, S Fabre, D Moukoko, C Jorgensen, and D Noel
Phenotypic and functional characterisation of ovine mesenchymal stem cells: application to a cartilage defect model
Ann Rheum Dis, March 1, 2008; 67(3): 288 - 295.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
F. Juthier, A. Vincentelli, J. Gaudric, D. Corseaux, O. Fouquet, C. Calet, T. L. Tourneau, V. Soenen, C. Zawadzki, O. Fabre, et al.
Decellularized heart valve as a scaffold for in vivo recellularization: Deleterious effects of granulocyte colony-stimulating factor
J. Thorac. Cardiovasc. Surg., April 1, 2006; 131(4): 843 - 852.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
Y. Isomatsu, T. Shin'oka, G. Matsumura, N. Hibino, T. Konuma, M. Nagatsu, and H. Kurosawa
Extracardiac total cavopulmonary connection using a tissue-engineered graft
J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1958 - 1962.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
K. Schenke-Layland, F. Opitz, M. Gross, C. Doring, K.J. Halbhuber, F. Schirrmeister, Th. Wahlers, and U.A. Stock
Complete dynamic repopulation of decellularized heart valves by application of defined physical signals--an in vitro study
Cardiovasc Res, December 1, 2003; 60(3): 497 - 509.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The Society of Thoracic Surgeons.